Adam Vigil, Ph.D.

2008 Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Virology Biology, Genetics, Immunology
"Adam Vigil"


Sign in to add mentor
Adolfo Garcia-Sastre grad student 2008 Mount Sinai School of Medicine
 (Recombinant Newcastle Disease Virus as a cancer therapeutic agent.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Vigil A, Estélles A, Kauvar LM, et al. (2018) Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses. Antimicrobial Agents and Chemotherapy
Varga JJ, Vigil A, DeShazer D, et al. (2012) Distinct human antibody response to the biological warfare agent Burkholderia mallei. Virulence. 3: 510-4
Vigil A, Davies DH, Felgner PL. (2010) Defining the humoral immune response to infectious agents using high-density protein microarrays Future Microbiology. 5: 241-251
Zamarin D, Martínez-Sobrido L, Kelly K, et al. (2009) Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 697-706
Vigil A, Martinez O, Chua MA, et al. (2008) Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1883-90
Vigil A, Park MS, Martinez O, et al. (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Research. 67: 8285-92
See more...